Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

E-Therapeutics Reports Loss as It Restarts Drug Discovery Unit

E-Therapeutics Plc, the U.K. drugmaker that issued almost 17 million pounds ($28 million) of new shares in March, lost more money for a second year as it worked to bring four medicines closer to clinical trials.

The loss for the 12 months ended Jan. 31 widened to 2.3 million pounds from 1.8 million pounds a year earlier, the Newcastle-upon-Tyne, England-based company said today in a statement. E-Therapeutics had no revenue for a second year.

The drugmaker raised 16.6 million pounds in March after shares surged 45 percent to restart its drug discovery unit near Oxford, England, and to prepare four treatments, including one to kill malignant cancer cells, for human testing next year. E-Therapeutics is also in talks with larger drugmakers, said Chief Executive Officer Malcolm Young. He declined to say which companies.

“It’s our principle priority to partner with much larger pharmaceutical companies,” said Young, who expects the discovery unit to identify a new drug in six to nine months, in a phone interview. “The sort of core financials don’t capture where we are at all.”

E-Therapeutics, which uses molecular databases to help it decide on which drugs may succeed in testing, has returned 4.3 percent in the past year. Shares were unchanged at 36.5 pence at 10:30 a.m. in London trading. The drug developer has a market value of 50 million pounds.

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.